You just read:

Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)

News provided by

Daiichi Sankyo Company, Limited

08 May, 2018, 08:00 BST